Anticalins versus antibodies: made-to-order binding proteins for small molecules
Chemistry & Biology, ISSN: 1074-5521, Vol: 7, Issue: 8, Page: 547-554
2000
- 17Citations
- 50Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes15
- CrossRef15
- 14
- Patent Family Citations2
- Patent Families2
- Captures50
- Readers50
- 50
Article Description
Engineering proteins to bind small molecules presents a challenge as daunting as drug discovery, for both hinge upon our understanding of receptor–ligand molecular recognition. However, powerful techniques from combinatorial molecular biology can be used to rapidly select artificial receptors. While traditionally researchers have relied upon antibody technologies as a source of new binding proteins, the lipocalin scaffold has recently emerged as an adaptable receptor for small molecule binding. ‘Anticalins’, engineered lipocalin variants, offer some advantages over traditional antibody technology and illuminate features of molecular recognition between receptors and small molecule ligands.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1074552100000168; http://dx.doi.org/10.1016/s1074-5521(00)00016-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033826861&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/11048945; https://linkinghub.elsevier.com/retrieve/pii/S1074552100000168; http://linkinghub.elsevier.com/retrieve/pii/S1074552100000168; http://api.elsevier.com/content/article/PII:S1074552100000168?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1074552100000168?httpAccept=text/plain; http://dx.doi.org/10.1016/s1074-5521%2800%2900016-8; https://dx.doi.org/10.1016/s1074-5521%2800%2900016-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know